Figure 3 | Scientific Reports

Figure 3

From: Novel PI3K/AKT targeting anti-angiogenic activities of 4-vinylphenol, a new therapeutic potential of a well-known styrene metabolite

Figure 3

Effects of 4VP on MMPs activities, expressions and VEGFRs expressions in HUVEC and HMEC-1 cells.

(A) Cells were treated with 4VP (20 or 40 μg/mL) for 24 hours and the MMP activities were determined by zymography. Representative zymograms were shown on HUVEC and HMEC-1 cells. The histograms showed the quantified results of enzyme activities. Western blot analyses of effects of 4VP on (B) MMPs and (D) VEGFRs expressions. Cells were treated with 4VP (20 or 40 μg/mL) for 24 or 48 hours. Immunoblotting was performed 3–4 times using independently prepared cell lysates and the representative blots were shown. The histograms showed the quantified results of protein levels, which were adjusted with corresponding β-actin protein levels. Quantitative RT-PCR analyses of (C) MMPs and (E) VEGFRs gene mRNA. Cells were treated with 4VP (20 or 40 μg/mL) for 24 hours. Data were normalized to corresponding GAPDH expressions in control cells. Proteins and mRNA expressions results are expressed as fold of control (mean fold of control + SD from 3–4 independent experiments). Differences between the treated and vehicle-treated control groups were determined by one-way ANOVA with Tukey’s post-hoc test. *p < 05, **p < 0.01, ***p < 0.005 as compared among groups.

Back to article page